Robert Hazlett
Stock Analyst
(0.75)
# 4,648
Out of 4,648 analysts
25
Total ratings
31.03%
Success rate
-19.52%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $10.17 | +135.99% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $1.33 | +200.75% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $2.41 | +480.91% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.26 | +7,507.46% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $87.25 | +12.32% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $3.90 | +1,438.46% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.68 | +1,246.15% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $16.46 | +76.18% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $86.17 | -53.58% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $7.95 | +326,944.03% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $1.85 | +224.32% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $27 | $11.63 | +132.16% | 2 | Oct 16, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $10.17
Upside: +135.99%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $1.33
Upside: +200.75%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $2.41
Upside: +480.91%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.26
Upside: +7,507.46%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $87.25
Upside: +12.32%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $3.90
Upside: +1,438.46%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.68
Upside: +1,246.15%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $16.46
Upside: +76.18%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $86.17
Upside: -53.58%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $7.95
Upside: +326,944.03%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.85
Upside: +224.32%
Oct 16, 2017
Maintains: Buy
Price Target: $18 → $27
Current: $11.63
Upside: +132.16%